| Literature DB >> 24386290 |
Sarah Vidick1, Baptiste Leroy2, Leonor Palmeira1, Bénédicte Machiels1, Jan Mast3, Sylvie François1, Ruddy Wattiez2, Alain Vanderplasschen1, Laurent Gillet1.
Abstract
Gammaherpesvirinae, such as the human Epstein-Barr virus (EBV) and the Kaposi's sarcoma associated herpesvirus (KSHV) are highly prevalent pathogens that have been associated with several neoplastic diseases. As EBV and KSHV are host-range specific and replicate poorly in vitro, animal counterparts such as Murid herpesvirus-4 (MuHV-4) have been widely used as models. In this study, we used MuHV-4 in order to improve the knowledge about proteins that compose gammaherpesviruses virions. To this end, MuHV-4 extracellular virions were isolated and structural proteins were identified using liquid chromatography tandem mass spectrometry-based proteomic approaches. These analyses allowed the identification of 31 structural proteins encoded by the MuHV-4 genome which were classified as capsid (8), envelope (9), tegument (13) and unclassified (1) structural proteins. In addition, we estimated the relative abundance of the identified proteins in MuHV-4 virions by using exponentially modified protein abundance index analyses. In parallel, several host proteins were found in purified MuHV-4 virions including Annexin A2. Although Annexin A2 has previously been detected in different virions from various families, its role in the virion remains controversial. Interestingly, despite its relatively high abundance in virions, Annexin A2 was not essential for the growth of MuHV-4 in vitro. Altogether, these results extend previous work aimed at determining the composition of gammaherpesvirus virions and provide novel insights for understanding MuHV-4 biology.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24386290 PMCID: PMC3875534 DOI: 10.1371/journal.pone.0083842
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Assessment of MuHV-4 virion purity.
The purity of the virions (i and ii) and capsid-tegument fractions (iii and iv) preparations was assessed by negative staining and electron microscopy. Scale bars are shown on the images.
Viral content of MuHV-4 extracellular virions.
| 1D nanoLC-MS/MS | Deglyco-1D nanoLC-MS/MS | ||||||||||
| ORF | Protein description | Predicted MM (kDa) | pK | No. of peptides | Prot matches | Coverage (%) | emPAI (% of max)fg | No. of peptides | Prot matches | Coverage (%) | emPAI (% of max)fg |
| M3 | Chemokine binding protein | 44.94 | + | 11 | 27 | 36.45 | 19 | ||||
| ORF4 | Glycoprotein gp70 | 42.98 | + | 9 | 72 | 22.68 | 28 | 1 | 3 | 2,58 | 2 |
|
|
| 96.53 | + | 33 | 121 | 53.00 | 28 | 29 | 141 | 49,12 | 58 |
| ORF11 | Potential tegument protein | 43.07 | + | 12 | 64 | 53.09 | 27 | 4 | 10 | 20,10 | 9 |
| ORF17 | Minor scaffold protein (protease) | 59.37 | + | 3 | 5 | 5.33 | 2 | ||||
| ORF19 | Capsid vertex-specific complex protein | 57.71 | + | 8 | 23 | 20.93 | 9 | 4 | 9 | 12,79 | 6 |
| ORF21 | Thymidine kinase. potential tegument protein | 72.85 | + | 39 | 471 | 68.01 | 80 | 14 | 65 | 29,04 | 25 |
|
|
| 83.75 | + | 29 | 173 | 40.96 | 46 | 15 | 82 | 31,10 | 22 |
| ORF23 | Egress protein | 42.97 | + | 18 | 99 | 72.97 | 68 | 10 | 22 | 46,19 | 34 |
|
|
| 154.38 | + | 76 | 526 | 71.30 |
| 49 | 554 | 51,27 |
|
|
|
| 33.84 | + | 13 | 99 | 61.20 | 127 | 11 | 58 | 60,87 | 142 |
| ORF27 | Glycoprotein gp48 | 29.65 | + | 9 | 86 | 36.61 | 43 | 5 | 10 | 24,80 | 23 |
|
|
| 8.59 | + | 1 | 17 | 18.67 | 19 | 1 | 3 | 18,67 | 21 |
| ORF32 | Capsid vertex-specific complex protein | 50.64 | + | 2 | 17 | 8.78 | 2 | 2 | 2 | 6,98 | 3 |
| ORF33 | Teg. myristoylated protein binding protein | 36.70 | + | 13 | 205 | 46.48 | 90 | 10 | 83 | 44,34 | 58 |
| ORF36 | Kinase | 49.93 | + | 3 | 5 | 9.61 | 2 | 1 | 1 | 2,97 | 1 |
| ORF38 | Tegument myristoylated protein | 8.34 | + | 1 | 4 | 10.67 | 7 | 1 | 2 | 10,67 | 9 |
| ORF39 | Glycoprotein M | 43.91 | + | 9 | 137 | 19.84 | 36 | 7 | 60 | 18,80 | 19 |
| ORF43 | Capsid portal protein | 64.61 | + | 2 | 2 | 4.23 | 1 | 1 | 1 | 4,06 | 1 |
|
|
| 22.51 | + | 3 | 8 | 42.23 | 6 | ||||
| ORF47 | Glycoprotein L | 15.35 | + | 4 | 15 | 48.18 | 14 | 2 | 10 | 24,82 | 26 |
| ORF51 | Glycoprotein gp150 | 50.03 | + | 1 | 30 | 5.18 | 3 | 1 | 3 | 5,18 | 1 |
|
|
| 14.85 | + | 12 | 417 | 64.44 | 5298 | 8 | 133 | 60,74 | 2312 |
| ORF55 | Tegument palmitoylated protein | 21.01 | – | 2 | 4 | 25.79 | 4 | ||||
| ORF58 | Glycoprotein | 40.62 | + | 2 | 2 | 6.05 | 1 | 1 | 1 | 3,17 | 2 |
| ORF62 | Triplex component | 36.98 | + | 27 | 137 | 88.99 | 177 | 16 | 60 | 66,97 | 116 |
| ORF63 | Large tegument protein binding protein | 103.31 | + | 2 | 3 | 2.66 | 1 | 1 | 1 | 1,77 | 1 |
| ORF64 | Tegument protein | 274.62 | + | 15 | 32 | 12.94 | 2 | 6 | 20 | 3,62 | 2 |
| ORF65 | Small capsomer interacting protein | 19.99 | + | 15 | 121 | 85.56 | 503 | 8 | 17 | 52,69 | 67 |
|
|
| 147.26 | + | 52 | 656 | 54.35 | 46 | 36 | 478 | 39,47 | 52 |
| ORF75B | Tegument protein/v-FGAM-synthetase | 144.37 | + | 36 | 390 | 46.27 | 25 | 25 | 202 | 30,12 | 30 |
a This approach was accomplished in three independent biological replicates and results were pooled.
b Proteinase K treatment. +. proteins detected in the Proteinase K - 1D gel/nanoLC-MS/MS.
c Number of unique peptides identified per protein.
d Number of peptides detected per protein.
e Values shown are the percentages of coverage of proteins by peptides.
f emPAI values were calculated as described by Ishihama et al. [42].
g Relative emPAI values were calculated as percentages of pORF25 abundance for each individual replicate and mean values were calculated.
h Proteins previously identified in MuHV-4 virions [26] are highlighted in bold.
Figure 2Sensitivity of viral proteins to proteinase K treatment of virions.
Western blotting analysis of viral proteins in purified virions from mock (–) and proteinase K (+) treated samples. Gp150 and gN are type I transmembrane proteins which have a N-terminal domain predicted to be sensitive to proteinase K digestion.
Proteins of MuHV-4 virions identified by 1D gel/nanoLC-MS/MS as associated with purified capsid-tegument samples.
| ORF | Protein description | Predicted MM (kDa) | Proteinase K | No. of peptides | Prot matches | Covergae | emPAI (% of max) | Expected relative abundance in capsid (%) |
| ORF11 | Potential tegument protein | 43.07 | + | 11 | 31 | 52,32 | 14,04 | |
|
|
| 59.37 | + | 7 | 35 | 14,34 | 3,16 | 15.7 |
|
|
| 57.71 | + | 10 | 28 | 31,20 | 7,02 | up to 6.28 |
| ORF21 | Thimidine kinase | 72.85 | + | 23 | 200 | 50,31 | 24,97 | |
| ORF23 | Egress protein | 42.97 | + | 14 | 44 | 51,71 | 24,02 | |
|
|
| 154.38 | + | 70 | 527 | 70,65 | 100,00 | 100 |
|
|
| 33.84 | + | 11 | 73 | 60,87 | 91,32 | 67 |
|
|
| 50.64 | + | 6 | 19 | 20,72 | 5,97 | up to 6.28 |
| ORF33 | Tegument protein | 36.70 | + | 9 | 45 | 44,04 | 12,79 | |
| ORF36 | Kinase | 49.93 | + | 6 | 11 | 17,16 | 3,31 | |
|
|
| 64.61 | + | 20 | 29 | 47,97 | 16,45 | 1.25 |
| ORF52 | Tegument protein | 14.85 | + | 10 | 129 | 69,63 | 1066,10 | |
|
|
| 36.98 | + | 20 | 96 | 86,54 | 175,63 | 33.5 |
| ORF63 | Tegument protein | 103.31 | + | 14 | 33 | 21,82 | 3,46 | |
| ORF64 | Tegument protein | 274.62 | + | 41 | 78 | 25,56 | 3,96 | |
|
|
| 20.00 | + | 11 | 77 | 75,81 | 282,00 | 94.2 |
| ORF75C | Tegument protein/v-FGAM-synthetase | 147.26 | + | 39 | 287 | 45,95 | 14,99 | |
| ORF75B | Tegument protein/v-FGAM-synthetase | 144.37 | + | 32 | 147 | 41,33 | 9,43 |
a Proteinase K treatment. +, proteins detected in the Proteinase K - 1D gel/nanoLC-MS/MS analysis of virions.
b Number of unique peptides identified per protein.
c Number of peptides detected per protein.
d Values shown are the percentages of coverage of proteins by peptides.
e emPAI values were calculated as described by Ishihama et al., [42].
f Relative emPAI values were calculated as percentages of pORF25 abundance.
g As described for HSV-1B- capsids by Baines et al., [9].
h Predicted capsid proteins are highlighted in bold.
i On the basis of full occupancy, i.e. one copy decorating each of 6 hexon tips.
Figure 3Proteogenomic map of MuHV-4 structural peptides.
The 6 possible frames of the MuHV-4 genome (AF105037.1) translation are shown with rectangle indicating annotated ORFs. Red and blue ORFs represent forward and reverse frames respectively. Detected peptides are shown by bars whose the height is proportional to the number of detections. Genomic positions in bp are indicated.
Figure 4Analysis of MuHV-4 structural protein glycosylation.
Control or deglycosylated proteins of purified MuHV-4 virions were separated by SDS-PAGE. After migration, each sample was divided in 30 serial slices along the lane and proteins of each slice were identified as described in the Materials and Methods. For the two treatments, slices containing M3, ORF4 (gp70), ORF8 (gB), ORF22 (gH), ORF27 (gp48), ORF28, ORF39 (gM), ORF47 (gL), ORF51 (gp150) and ORF58 proteins are shown with color intensity indicating the mean relative abundance (emPAI). For each lane, the abundances are expressed relatively to the band displaying the highest emPAI which is taken as 1. For each protein, predicted molecular mass is shown (theoretical lane). For the gB protein, the dashed slice indicated the predicted position of gB proteins before potential cleavage by cellular furin. The position of a MM standard is shown on the left.
Cellular proteins detected in MuHV-4 virions and comparison to other herpesviruses.
| RelativeeMPAI (%) | pK |
|
|
| |||||||
| Rhadinoviruses | Maca- | Lymph- | Simpl- | Varicel- | Cyto- | ||||||
| Protein description | Acc. N° | KSHV | BoHV-4 | AlHV-1 | EBV | HSV-1 | PRV | HCMV | |||
|
| |||||||||||
| Rab-1A isoform 1 | gi|4758988 | 9.7 |
| + | |||||||
| Rab-6A isoform 2 | gi|13195674 | 10.3 |
| + | + | ||||||
| Rab GDP diss.inhib.beta-like | gi|354465044 | 0.9 |
| + | |||||||
| Immunity-ass.nucleotide 4 | gi|13569476 | 1.2 |
| ||||||||
| Vesicle transport protein | gi|344256341 | 2.0 |
| ||||||||
| ADP-ribosylation factor 2 | gi|6671571 | 8.7 |
| + | |||||||
| Ras-related protein Rab-14 | gi|16758368 | 4.3 |
| + | |||||||
|
| |||||||||||
| Casein kinase II subunit beta | gi|7106277 | 3.1 |
| + | + | + | |||||
| Annexin A3 | gi|344255510 | 1.3 |
| ||||||||
| CD 81 antigen | gi|194135609 | 10.5 |
| ||||||||
| S/T-protein Pase PP1-alpha | gi|4506003 | 5.3 |
| + | + | ||||||
| Thy-1 membrane glycoprotein | gi|344240805 | 3.0 |
| + | |||||||
|
| |||||||||||
| Cofilin-2 | gi|6671746 | 3.6 |
| + | + | ||||||
| Microtubule-ass prot.RP | gi|7106301 | 3.1 |
| ||||||||
| Protein 88B | gi|109463441 | 0.4 |
| ||||||||
| Moesin | gi|344240889 | 1.4 |
| + | + | ||||||
| Tetraspanin | gi|685221 | 1.8 |
| ||||||||
|
| |||||||||||
| Histone H2A type 1 | gi|344240017 | 14.9 |
| ||||||||
| Histone H4 | gi|344240018 | 3.7 |
| + | |||||||
|
| |||||||||||
| VAMP 3 | gi|6678553 | 12.3 |
| + | |||||||
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
| |||
|
| |||||||||||
| GAPDH | gi|56188 | 2.2 |
| + | + | + | + | ||||
| F1-ATPase beta subunit | gi|203033 | 1.3 |
| ||||||||
|
| |||||||||||
| VDAC-1 | gi|344238883 | 2.8 |
| ||||||||
|
| |||||||||||
| Protein CLEC16A-like | gi|348584902 | 0.4 |
| ||||||||
|
| |||||||||||
| PPIase A | gi|351706205 | 13.0 |
| ||||||||
| Anionic trypsin-1 precursor | gi|6981420 | 4.3 |
| ||||||||
| Polyubiquitin | gi|1050930 | 4.7 |
| + | |||||||
| GroEL_like type I chaperonin | gi|51452 | 0.8 |
| ||||||||
|
| |||||||||||
| C4BP | gi|354471099 | 0.6 |
| ||||||||
a Relative eMPAI values were calculated as the eMPAI values calculated for each analysis relatively to the abundance of pORF25 taken as 100%.
b Beta-, Beta-herpesvirinae; Maca-, Macaviruses; Lymph-, lymphocryptoviruses; Simpl-, simplexviruses; Varicel-, varicelloviruses; Cyto-, cytomegaloviruses.
pK: Proteinase K treatment. +, proteins detected in the Proteinase K - 1D gel/nanoLC-MS/MS.
Based on previously published studies.
Proteins previously identified in MuHV-4 virions [26] are highlighted in bold.
Figure 5Growth of MuHV-4 on Annexin A2 deficient mouse embryonic fibroblasts.
MEF cells from WT and Annexin A2-null mice were infected with BAC+ MuHV-4 virions at a MOI of 0.01 for multi-step assay as described in the Materials and Methods. Supernatants of infected cultures or infected cells were harvested at successive intervals and the amount of infectious virus determined by plaque assay on BHK-21 cells. Plaques were visualized by fluorescent detection of eGFP. The data presented are the average ± SEMs for triplicate measurements. The data were analyzed by 2way ANOVA and Bonferroni posttests. MuHV-4 growths on these two different cell types were not statistically different.
Figure 6Schematic representation of the protein composition of mature extracellular MuHV-4 virions.
Capsid proteins are represented as hexagons, tegument proteins as circles, envelope proteins as triangles. As the location of the M3 protein is unknown, it is represented as a putative structural protein (square). The predicted protein mass is directly proportional to their surface. The mean relative abundance (emPAI) determined by the different analyses of complete virions is indicated in color intensity (see scale).